NewsAndPress

 

  • January 2016 - SK-Pharma invests one fifth of its global annual sales in research and development (R&D) of new innovative treatments and drugs.

  • September 2015 - Garan SK accelerates its emerging markets growth strategy with a portfolio of products in CIS and Latin America.

  • June 2015 - KS Kim significantly increases its portfolio and presence in the Israeli market.

  • October 2014 - Garan SK launches Alprostadil in Kazakhstan.

  • September 2014 - 2014 GF Bio begins pre-clinical studies for GF 473

  • May 2014 - KS Kim launches the gastrointestinal drug Pantoprazole in Israel. Pantoprazole belongs to the group of drugs called proton pump inhibitors. It decreases the amount of acid produced in the stomach. Pantoprazole is used to treat erosive esophagitis (damage to the esophagus from stomach acid) and other conditions involving excess stomach acid such as Zollinger-Ellison syndrome.

  • March 2014 - 2014 KS Kim launches Meropenem in Israel

  • January 2014 - 2014 Garan SK launches its ARV drug portfolio in Kazakhstan

  • October 2013 - 2013 SK Pharma signs its first distribution agreement in Latin America

  • November 2012 - Garan SK launches biosimilar Enoxaparin sodium injection, used for prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery, or in medical patients with severely restricted mobility during acute illness; and also for the treatment of acute DVT.